Modified DNA Aptamer PNDA-3 Periostin Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments lack effective and specific targeting of periostin, a protein involved in cancer development and metastasis, leading to inadequate inhibition of cancer growth and metastasis, particularly in breast cancer.
Innovation Solution
Development of a modified DNA aptamer, PNDA-3, which specifically binds to periostin with high affinity, blocking interactions with integrin αvβ3 and αvβ5, thereby inhibiting adhesion, migration, and invasion of breast cancer cells, and reducing cancer growth and metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies are used, then cancer treatment is provided, but they lack specific targeting of periostin and exhibit toxicity to normal cells
Solution Approach 1:
The patent uses an aptamer as an intermediary molecule that specifically binds to periostin, blocking its interaction with integrin receptors. This mediator approach allows targeted inhibition of cancer progression without the broad toxicity associated with conventional chemotherapy, as the aptamer selectively interacts only with the periostin-integrin pathway in cancer cells.
Solution Approach 2:
The patent employs modified nucleotide bases (5-benzyldeoxyuridine, 5-naphthyldeoxyuridine) to change the chemical parameters of the aptamer structure. These modifications enhance binding affinity and specificity for periostin while improving stability, allowing the therapeutic agent to achieve effective targeting without affecting normal cells.
2Productivity
If periostin function is not targeted, then general cancer therapy is provided, but inhibition of cancer growth and metastasis is inadequate
Solution Approach 1:
The patent extracts and targets the specific periostin-integrin interaction pathway that drives cancer progression. By designing an aptamer that selectively binds to periostin, the invention isolates and inhibits this critical metastatic pathway without interfering with other cellular functions, thereby achieving effective cancer growth and metastasis inhibition with high specificity.
3Reliability
If aptamer is designed with modified bases for high affinity binding, then binding specificity to periostin is improved, but aptamer structure complexity increases
Solution Approach 1:
The patent applies modifications locally at specific positions within the aptamer sequence (incorporating 5-20 modified bases out of 25-100 total bases) rather than uniformly throughout the entire structure. This localized modification strategy enhances binding affinity and specificity for periostin while maintaining manageable overall structural complexity and facilitating practical synthesis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
PNDA-3 effectively inhibits cancer cell adhesion, migration, and invasion, and decreases breast cancer growth and metastasis in mouse models, offering a promising therapeutic and diagnostic tool for targeting periostin in cancer treatment.
Implementation Method 1
modified bases that are substituted with a hydrophobic functional group selected from the group consisting of a naphthyl group, a benzyl group, a pyrrole benzyl group, and tryptophan
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
This disclosure relates to DNA aptamer specifically binding to periostin, which is cancer-related protein, a composition for inhibiting cancer and/or cancer metastasis and/or a composition for diagnosis of cancer and/or cancer metastasis, comprising the same as an active ingredient, wherein the aptamer has different binding mechanism from the existing antibodies, and thus, may inhibit and diagnose cancer/cancer metastasis more effectively.